1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.2471/blt.06.031518" target="_blank" rel="noreferrer">http://doi.org/10.2471/blt.06.031518</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Rare essentials: drugs for rare diseases as essential medicines
Publisher
An entity responsible for making the resource available
Bulletin Of The World Health Organization
Date
A point or period of time associated with an event in the lifecycle of the resource
2006
Subject
The topic of the resource
Humans; decision making; Health Services Accessibility; Needs Assessment; Risk Assessment; Cost-Benefit Analysis; Organizational Policy; Public Health Administration; Policy Making; Rare Diseases; Organizational; Resource Allocation; Health Priorities; Drugs; World Health Organization; Essential; Orphan Drug Production; Social Justice
Creator
An entity primarily responsible for making the resource
Stolk P; Willemen Marjolein JC; Leufkens HGM
Description
An account of the resource
Since 1977, the WHO Model List of Essential Medicines (EML), published by WHO, has provided advice for Member States that struggle to decide which pharmaceutical technologies should be provided to patients within their public health systems. Originating from outside WHO, an incentive system has been put in place by various governments for the development of medicines for rare diseases ("orphan drugs"). With progress in pharmaceutical research (e.g. drugs targeted for narrower indications), these medicines will feature more often on future public health agendas. However, when current definitions for selecting essential medicines are applied strictly, orphan drugs cannot be part of the WHO Essential Medicines Programme, creating the risk that WHO may lose touch with this field. In our opinion WHO should explicitly include orphan drugs in its policy sphere by composing a complementary Orphan Medicines Model List as an addition to the EML. This complementary list of "rare essentials" could aid policy-makers and patients in, for example, emerging countries to improve access to these drugs and stimulate relevant policies. Furthermore, inconsistencies in the current EML with regard to medicines for rare diseases can be resolved. In this paper we propose selection criteria for an Orphan Medicines Model List that could form a departure point for future work towards an extensive WHO Orphan Medicines Programme.
2006-09
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2471/blt.06.031518" target="_blank" rel="noreferrer">10.2471/blt.06.031518</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2006
Backlog
Bulletin Of The World Health Organization
Cost-Benefit Analysis
Decision Making
Drugs
Essential
Health Priorities
Health Services Accessibility
Humans
Journal Article
Leufkens HGM
Needs Assessment
Organizational
Organizational Policy
Orphan Drug Production
Policy Making
Public Health Administration
Rare Diseases
Resource Allocation
Risk Assessment
Social Justice
Stolk P
Willemen Marjolein JC
World Health Organization